Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ERN2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ERN2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ERN2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/ERN2_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00349761 | Colorectum | SER | response to endoplasmic reticulum stress | 74/2897 | 256/18723 | 3.01e-08 | 2.05e-06 | 74 |
GO:00700591 | Colorectum | SER | intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress | 25/2897 | 63/18723 | 2.92e-06 | 1.18e-04 | 25 |
GO:00359661 | Colorectum | SER | response to topologically incorrect protein | 46/2897 | 159/18723 | 1.14e-05 | 3.63e-04 | 46 |
GO:00359671 | Colorectum | SER | cellular response to topologically incorrect protein | 36/2897 | 116/18723 | 1.88e-05 | 5.51e-04 | 36 |
GO:00442701 | Colorectum | SER | cellular nitrogen compound catabolic process | 99/2897 | 451/18723 | 1.46e-04 | 2.86e-03 | 99 |
GO:00069861 | Colorectum | SER | response to unfolded protein | 38/2897 | 137/18723 | 1.68e-04 | 3.16e-03 | 38 |
GO:00467001 | Colorectum | SER | heterocycle catabolic process | 97/2897 | 445/18723 | 2.20e-04 | 3.89e-03 | 97 |
GO:00346201 | Colorectum | SER | cellular response to unfolded protein | 28/2897 | 96/18723 | 4.78e-04 | 6.89e-03 | 28 |
GO:19013611 | Colorectum | SER | organic cyclic compound catabolic process | 104/2897 | 495/18723 | 5.46e-04 | 7.63e-03 | 104 |
GO:00346551 | Colorectum | SER | nucleobase-containing compound catabolic process | 88/2897 | 407/18723 | 5.53e-04 | 7.71e-03 | 88 |
GO:00194391 | Colorectum | SER | aromatic compound catabolic process | 98/2897 | 467/18723 | 8.09e-04 | 1.01e-02 | 98 |
GO:00064011 | Colorectum | SER | RNA catabolic process | 62/2897 | 278/18723 | 1.56e-03 | 1.67e-02 | 62 |
GO:00336741 | Colorectum | SER | positive regulation of kinase activity | 95/2897 | 467/18723 | 2.62e-03 | 2.41e-02 | 95 |
GO:00458601 | Colorectum | SER | positive regulation of protein kinase activity | 79/2897 | 386/18723 | 4.85e-03 | 3.79e-02 | 79 |
GO:0036498 | Colorectum | SER | IRE1-mediated unfolded protein response | 8/2897 | 19/18723 | 4.95e-03 | 3.84e-02 | 8 |
GO:00719001 | Colorectum | SER | regulation of protein serine/threonine kinase activity | 74/2897 | 359/18723 | 5.22e-03 | 3.96e-02 | 74 |
GO:00064012 | Colorectum | MSS | RNA catabolic process | 102/3467 | 278/18723 | 5.07e-13 | 1.02e-10 | 102 |
GO:00971932 | Colorectum | MSS | intrinsic apoptotic signaling pathway | 102/3467 | 288/18723 | 6.06e-12 | 9.82e-10 | 102 |
GO:00442702 | Colorectum | MSS | cellular nitrogen compound catabolic process | 141/3467 | 451/18723 | 2.95e-11 | 3.83e-09 | 141 |
GO:00467002 | Colorectum | MSS | heterocycle catabolic process | 139/3467 | 445/18723 | 4.37e-11 | 5.05e-09 | 139 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ERN2 | SNV | Missense_Mutation | | c.920G>A | p.Gly307Glu | p.G307E | Q76MJ5 | protein_coding | deleterious(0) | benign(0.305) | TCGA-A8-A08J-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
ERN2 | SNV | Missense_Mutation | novel | c.541A>C | p.Thr181Pro | p.T181P | Q76MJ5 | protein_coding | deleterious(0.01) | possibly_damaging(0.85) | TCGA-AC-A3W5-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | CR |
ERN2 | SNV | Missense_Mutation | novel | c.424N>A | p.Glu142Lys | p.E142K | Q76MJ5 | protein_coding | tolerated(0.13) | benign(0.018) | TCGA-AC-A3W6-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ERN2 | SNV | Missense_Mutation | novel | c.1089C>G | p.His363Gln | p.H363Q | Q76MJ5 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AC-A8OQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ERN2 | SNV | Missense_Mutation | | c.1450N>A | p.Ser484Thr | p.S484T | Q76MJ5 | protein_coding | tolerated(0.18) | benign(0.001) | TCGA-AR-A0TS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
ERN2 | SNV | Missense_Mutation | novel | c.2068G>A | p.Glu690Lys | p.E690K | Q76MJ5 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AR-A5QM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | PD |
ERN2 | SNV | Missense_Mutation | | c.1905N>A | p.His635Gln | p.H635Q | Q76MJ5 | protein_coding | deleterious(0.02) | probably_damaging(0.998) | TCGA-B6-A0I8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
ERN2 | SNV | Missense_Mutation | novel | c.1037A>C | p.Tyr346Ser | p.Y346S | Q76MJ5 | protein_coding | tolerated(0.06) | benign(0.131) | TCGA-BH-A0BR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ERN2 | SNV | Missense_Mutation | | c.2434N>A | p.Glu812Lys | p.E812K | Q76MJ5 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
ERN2 | SNV | Missense_Mutation | rs751236768 | c.2707N>C | p.Glu903Gln | p.E903Q | Q76MJ5 | protein_coding | deleterious(0.01) | possibly_damaging(0.748) | TCGA-C8-A275-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |